Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC for the resale of 1,192,023,200 ordinary shares represented by 2,980,058 American Depositary Shares (ADSs). The selling shareholders identified in the prospectus will be reselling these shares. The ordinary shares include those issued in private placement transactions in December 2023 and shares issuable upon the exercise of pre-funded warrants issued in the same placements. The selling shareholders may sell the shares on the market or in private transactions at fixed or negotiated prices using various methods including block trades or through broker-dealers. Biodexa Pharmaceuticals will not receive any proceeds from the sale of the shares by the selling shareholders. However, the company may receive proceeds from the...Show More

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC for the resale of 1,192,023,200 ordinary shares represented by 2,980,058 American Depositary Shares (ADSs). The selling shareholders identified in the prospectus will be reselling these shares. The ordinary shares include those issued in private placement transactions in December 2023 and shares issuable upon the exercise of pre-funded warrants issued in the same placements. The selling shareholders may sell the shares on the market or in private transactions at fixed or negotiated prices using various methods including block trades or through broker-dealers. Biodexa Pharmaceuticals will not receive any proceeds from the sale of the shares by the selling shareholders. However, the company may receive proceeds from the exercise of warrants in certain circumstances. The company has also agreed to indemnify the selling shareholders against certain liabilities. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX', with the last reported closing price on May 2, 2024, being $1.27. The prospectus also includes information on risks involved in investing in the securities, use of proceeds, dividend policy, capitalization, and details on the selling shareholders. The company has appointed an agent for service of process in the U.S. and has agreed to keep the prospectus effective until the securities can be sold without registration or until all have been sold.